Zambia Medicines Regulatory Authority (ZAMRA) Tuesday,29th December, 2020 Press Statement on Purchase and Use of Rufedol Nouvelle Tablets

Rufedol Tablets

ZAMBIA MEDICINES REGULATORY AUTHORITYPRESS STATEMENT

                                                                                                                   FOR IMMEDIATE RELEASE

PURCHASE AND USE OF RUFEDOL NOUVELLE TABLETS

Lusaka, Tuesday,29^TH December, 2020…………It has come to the attention of the Authority that there is a medicine on the Zambian market called Rufedol Nouvelle Tablets, containing Paracetamol 325mg and Diclofenac 50mg as active ingredients.

The product is labelled in French and is not authorised for sale on the Zambian market.

The authorised product is Rufedol Tablets, containing Paracetamol 500mg and Diclofenac 50mg as APIs, and bearing the Marketing Authorisation number of 075/018.

In this regard, we wish to advise the general public against the purchase and use of Rufedol Nouvelle Tablets because its quality and safety has not been ascertained and may cause harm to the users.

The Authority further wishes to advise persons in possession of Rufedol Nouvelle Tablets to immediately inform the Authority and make arrangements for proper disposal of the product; failure to which they risk prosecution by Law.

As part of meeting its mandate, the Authority regulates and controls the manufacture, importation, exportation, distribution and sale of medicines and allied substances.

Further, ZAMRA serves and protects public interest in all matters relating to medicines and allied substances.

Issued by

 Christabel Mutale Iliamupu (Mrs)

Senior Public Relations Officer

Zambia Medicines Regulatory Authority

Tel:+260 211 220 429,Email:pharmacy@zamra.co.zm, Website: www.zamra.co